GlassScriptPhysician profile
David D Bryan
NPI 1700848777
$3,325.66
in general payments reported to CMS, 2019-2025
24 companies · $507 in 2025
The $507 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $135 · 2021: $265 · 2022: $809 · 2023: $755 · 2024: $409 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,670.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $686.72 | 2019-2025 | Clareon, Hydrus Microstent |
| Oyster Point Pharma, INC. | $582.57 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $276.29 | 2021-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $249.09 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $209.74 | 2022-2025 | Acthar |
| Johnson & Johnson Vision Care, INC. | $167.55 | 2022-2024 | Acuvue |
| Sun Pharmaceutical Industries INC. | $150.14 | 2021-2023 | Cequa |
| Bausch & Lomb Americas INC. | $140.55 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Amgen INC. | $132.22 | 2025 | Tepezza |
| Kala Pharmaceuticals, INC. | $128.20 | 2020-2022 | |
| Abbvie INC. | $121.23 | 2022-2025 | Lumigan |
| Allergan, INC. | $95.68 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $62.88 | 2019-2021 | |
| Shire North American Group INC | $41.07 | 2019 | |
| Thea Pharma INC. | $37.45 | 2022-2024 | Iyuzeh |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $35.40 | 2022-2023 | Tepezza |
| Dompe US, INC. | $34.74 | 2025 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $33.52 | 2019-2020 | |
| Harrow Eye, LLC | $32.32 | 2024 | Vevye |
| Tarsus Pharmaceuticals, INC. | $32.24 | 2025 | Xdemvy |
| Biotissue Holdings INC. | $20.00 | 2025 | |
| Merz Pharmaceuticals, LLC | $19.17 | 2025 | Xeomin |
| Astellas Pharma US INC | $18.84 | 2025 | Izervay |
| Alexion Pharmaceuticals, INC. | $18.05 | 2023 | Soliris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.